TP53-Mutant CHIP Marks a High-Risk CAR-T Phenotype
A peer-reviewed, single-center study of 104 recipients of commercial CD19- or BCMA-directed CAR-T therapy found that overall clonal hematopoiesis was not associated with toxicity or survival. A small TP53-mutant CHIP subgroup, however, had worse…
